I will be interested to see how they value potential deal given OPT302 is only part of the medication for wAMD. I guess it will in effect be used with a 'generic' by the time its approved, so the patent protected enhanced treatment should carry close to the full value of the combination treatment. It will also depend on whether any deal locks out competitor products from also being used in a combination therapy with OPT302.
Ann: Opthea's OPT-302 Granted Fast-Track for wet AMD, page-35
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
84.0¢ |
Change
0.015(1.82%) |
Mkt cap ! $1.055B | |||
| Open | High | Low | Value | Volume |
| 82.0¢ | 87.0¢ | 81.0¢ | $2.870M | 3.370M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 688 | 90.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 79.5¢ | 3888 | 2 |
View Market Depth
| Last trade - 15.59pm 04/10/2024 (20 minute delay) ? |
| OPT (ASX) Chart |